Early fulminant leukaemia post autologous bone marrow transplantation in non-Hodgkin's lymphoma patients

A. Toren, G. Rechavi, A. Nagler*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Although autologous bone marrow transplantation (ABMT) is a curative option for about 50% of the patients with progressive or relapsing lymphomas, considerable concern has been raised recently over the emerging rates of secondary malignancies following ABMT. A 15% cumulative incidence of myelodysplasia 5 years after BMT is of major concern. We hereby describe a unique form of leukaemia occurring 4-6 weeks post ABMT for non-Hodgkin's lymphoma patients. The possible etiology for this phenomenon as well as its relation to the classical MDS post ABMT is discussed.

Original languageEnglish
Pages (from-to)109-112
Number of pages4
JournalMedical Oncology
Volume15
Issue number2
DOIs
StatePublished - Jul 1998

Keywords

  • Acute myeloid leukemia (AML)
  • Myelodysplasia (MDS)
  • Non-Hodgkin's lymphoma (NHL)

Fingerprint

Dive into the research topics of 'Early fulminant leukaemia post autologous bone marrow transplantation in non-Hodgkin's lymphoma patients'. Together they form a unique fingerprint.

Cite this